Afinitor's Pancreatic Tumor Indication Limited To Progressive Disease

FDA approval of Novartis' everolimus for progressive pancreatic neuroendocrine tumors is in line with the Oncologic Drugs Advisory Committee's recommendations that the drug be reserved for those patients with more serious disease.